|
Jun 24, 2009 TRANS GENIC INC. |
|
Launch of Anti GPCR Monoclonal Antibodies | |||||||||||||||||||
We hereby announce that TRANS GENIC INC. (headquartered in Kumamoto, Japan, CEO: Ken-ichi Yamamura, hereinafter referred to as "we") has released anti GPCR monoclonal antibodies developed by GANP® Mouse Technology as research reagents on June 24, 2009. Details of the products are as follows. |
|||||||||||||||||||
|
|||||||||||||||||||
| Distribution method: | Sold through our distributors (Cosmo Bio Co., Ltd., Funakoshi Corporation, Wako Pure Chemical Industries, Ltd.) | ||||||||||||||||||
| Annual Sales Prospect: 50 - 100 units/ each | |||||||||||||||||||
| We are developing high-affinity and high-specificity antibodies by using GANP® Mouse Technology (hereinafter referred to as "the Technology"). Some of these antibodies are sold as research reagents and used in developing new diagnostic methods for various diseases including cancer. | |||||||||||||||||||
| Last year, we started a large project to develop antibodies targeting GPCRs (G Protein Coupled Receptor) with the Technology. The products launched this time are the first achievement of the project. | |||||||||||||||||||
| The reason why we targeted GPCRs is there are a large number of medicines targeting GPCRs and many pharmaceutical companies and universities are promoting drug discovery and basic researches on them. We intend to continue to develop anti GPCR monoclonal antibodies and offer them as research reagents to laboratories at home and abroad to support progress of life-science including drug discovery researches based on elucidation of life phenomenon and disease mechanism. |
|||||||||||||||||||
| The effects of the product launch on our business performance are immaterial, but we intend to make an announcement in the future when it starts to have a significant impact on our business performance. | |||||||||||||||||||
Reference: |
|||||||||||||||||||
| GANP® Mouse Technology | |||||||||||||||||||
| This is our unique technology to produce high-affinity and high-specificity antibodies using genetically engineered mice named "GANP® mice". We regard the technology as a fundamental technology in our antibody-related technological platforms and use it to promote various businesses, such as developing our original products and granting its license to pharmaceutical companies and diagnostic reagent manufacturers to gain profits from its licensing fees and product royalties. | |||||||||||||||||||
| - What is GANP (Germinal Center Associated Nuclear Protein)? It is a gene expressed in B-cells which produce antibodies. It was discovered by Dr. Nobuo Sakaguchi of Kumamoto University. |
|||||||||||||||||||
| - What is a GANP® mouse? It is a mouse transfected with GANP gene. |
|||||||||||||||||||
| Sakaguchi N. et al., J Immunol. 2005 Apr 15; 174(8):4485-94. | |||||||||||||||||||
| FFAR2 (GPR43) | |||||||||||||||||||
| FFAR2, also known as GPR43, is predominantly expressed in peripheral blood leukocytes and in spleen, suggesting that GPR43 may play a role in various immune and inflammatory responses. A study by using GPR43-deficienct mice shows that activation of GPR43 in adypocytes leads to inhibition of lipolysis and results in the reduction of plasma free fatty acids level in vivo. |
|||||||||||||||||||
GPR39 |
|||||||||||||||||||
| GPR39 is a member of GPCR and belongs to the ghrelin receptor family. It is mainly expressed in the stomach, small intestine and brain and activated by Zn ions. It has been shown that GPR39 protects against oxidative and endoplasmic reticulum stress and cell death by increasing secretion of PEDF. | |||||||||||||||||||
P2RY12 |
|||||||||||||||||||
| P2RY12 is a member of GPCR and belongs to P2RY family. It is highly expressed in brain, spinal cord and blood platelets. The patients who have a congenital hemorrhagic disease caused by the inability of their platelet to aggregate in response to ADP contain 2-base-pair deletion in one of the P2RY12 alleles. | |||||||||||||||||||
 |
 |